Home Newsfeeds JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

byBenzinga Newsdesk

January 20, 2023

1 minute read

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

News

Why Charles Schwab (SCHW) Stock Is Down 8%

By Henry Khederian

March 10, 3:51 PM

Charles Schwab Corporation Common Stock (NYSE: SCHW) shares are trading lower by 8.11% to $61.10 during Friday's session.

SCHW

Artelo Enters Next Phase Of Evaluation Of Its Cannabinoid Receptor Targeting Drug For The Treatment Of Cancer-Related Anorexia And Weight Loss

By Vuk Zdinjak

April 26, 8:59 AM

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, has initiated the phase 2a p

ARTL

Westwater Resources Announces First Off-Take Agreement for Sale of Graphite from its Kellyton Plant, Financial Terms Unidsclosed

By Benzinga Newsdesk

February 5, 7:36 AM

Westwater Resources, Inc. (NYSE:AMERICAN), an energy technology and battery-grade natural graphite company ("Westwater Resources" or "Westwater"), today announced the execution of its first off-take

AMERICAN